03.31.26 -- STREAM Edition: Take The Lead With A GS Cell Line Development Kit

Streamline cell and gene therapy with automated formulation and filling. Enhance scalability and reduce costs with closed systems for bulk media production. Solve your commercial manufacturing challenges.

A presentation reviews a risk-based framework for identity testing of ancillary raw materials, with emphasis on implementation based on product contact, material classification, and manufacturing stage.

See how this kit accelerates clone development to 14 weeks with ≥7 g/L protein titers while reducing costs through royalty-free commercial licensing for therapeutic applications.

 

Induced pluripotent stem cells (iPSCs) can go on to become any number of differentiated cell types, but what kinds of cells can become iPSCs? This section of Cell & Gene Live considers preferred starting materials.

In this segment of Cell & Gene Live, “Building Smarter Cell Therapies with AI and Synthetic Biology,” Tim Lu, M.D., Ph.D., and Claire Aldridge, Ph.D. explain, the complexity of cells requires moving beyond single gene intuition to large-scale design–build–test of gene circuits.

Explore how salt-active endonucleases overcome DNA clearance challenges in viral vector purification by digesting down to 3–5 nucleotides and performing reliably in high-salt conditions.